Clinical guideline recommendations for antipsychotic long-acting injections.
about
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaProfile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a reviewLong-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials.Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatryLong-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophreniaGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaPaliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoatePaliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review.Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.Long-acting injectable antipsychotics in early psychosis: a literature review.Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.Treatment adherence and social functioning in patients diagnosed with schizophrenia and treated with antipsychotic depot medication.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.Motivational aftercare planning to better care: Applying the principles of advanced directives and motivational interviewing to discharge planning for people with mental illness.Social and clinical descriptors of antipsychotic prescription.Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.Long-acting injectable antipsychotics in first-episode schizophrenia.Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.
P2860
Q24597701-C1BC0002-CA16-4699-A162-6EC9C3235559Q28084899-BF7FAFEB-DEE3-4CF7-A191-499FD273BA18Q30490054-7A924D61-0547-454B-80DD-8A11832EE25BQ34357174-E572C73B-3401-4020-9B55-F9752170424EQ34386881-492EC735-88C3-4217-AB70-76832AC06328Q34418847-83E9C643-0659-487B-8DA7-FC0BAB8ABB37Q35019258-A0B0CBC2-C0AD-4FC9-801A-0FAC20C4273DQ35073474-91B43214-86E6-4C46-9DCD-F27953B2B0CCQ35186007-3A7F67A5-7F00-4C79-A207-FB5711FC1F61Q35882300-0460471D-A818-4CCB-8765-00626E1521F6Q36169091-239B55B6-AF50-45CC-A0E4-9C13E6CFC2D0Q36183650-643A6B1A-742E-43E6-9D3C-BC39AA645B41Q36202865-F371121F-8105-4618-9FC6-FE30BB6E3AA4Q36489412-EBC2BE80-8575-469E-AEE3-843C36597A6BQ36568895-E4D7A3CD-A7E3-42E3-94E5-53BA0C462617Q36672952-94DB65DE-615E-4CCE-ACF3-E1D26B958085Q36698856-EE5DA481-176E-4280-95FB-C79D2EFE2889Q36981526-6E8AB939-AD60-4F66-AA75-9E41A986A21AQ37236148-A64D1DD4-8CAC-4C00-A0F3-F008402A2758Q37450910-DF18A65B-1103-4A7A-8FF7-E65843C22769Q37451403-036C3982-CB57-49B6-9055-57B2E1A030ABQ37465729-346D0E97-E182-4202-AA5E-EFC703BC4DFCQ37616971-D20F5759-ED3E-4743-B9EB-0A6D11BBDC96Q38008704-05B4226A-50A3-4D62-A417-D0704FAD041CQ38042430-7152DB02-8C9A-4196-A8F4-DA9BE0334CD7Q38064842-CBB738F8-0AE0-4BD5-8586-F367B9ADE10DQ38076170-EA73D97D-0A52-4A0A-8BD6-F02BFEED189AQ38150484-3DA5CA5D-A9F9-4104-ABCA-0EBCA8C5B9F0Q38451320-FDE37A6A-40D9-46EB-BD0A-EBB039560DD1Q38570636-75BF8669-AFCE-465A-AD73-3BE516EE0FCBQ38659006-D2D83098-444E-47D4-9865-46F5E45D0A83Q38851123-11AA5CFC-2A0F-4274-82BA-2C49FBAA98B0Q38851847-F92D86ED-86D6-4A88-B8C7-6EA68F377B2BQ39128141-D1F1F431-9144-4BED-A4C3-B2B847531CEFQ39343500-23F7C948-DFD6-4199-9818-2740702EE131Q40269113-CDA5DB76-193D-4B14-8B8A-81C32D94ADE7Q40278766-0C0DC201-3E8F-4273-921F-B4A757C4F622Q41991738-DF33245F-324B-48D6-8B33-E3EBCF29DCB7Q42149681-4DC80863-9BA9-4144-A826-4D34CDFD4F0EQ44733793-5C5EEC6C-7B2D-4DB8-B373-A7A1AF34C93F
P2860
Clinical guideline recommendations for antipsychotic long-acting injections.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Clinical guideline recommendations for antipsychotic long-acting injections.
@en
Clinical guideline recommendations for antipsychotic long-acting injections.
@nl
type
label
Clinical guideline recommendations for antipsychotic long-acting injections.
@en
Clinical guideline recommendations for antipsychotic long-acting injections.
@nl
prefLabel
Clinical guideline recommendations for antipsychotic long-acting injections.
@en
Clinical guideline recommendations for antipsychotic long-acting injections.
@nl
P356
P1476
Clinical guideline recommendations for antipsychotic long-acting injections.
@en
P2093
Carlos Garcia-Ribera
John M Kane
P356
10.1192/BJP.195.52.S63
P577
2009-11-01T00:00:00Z